Syndax Pharmaceuticals, Inc.
SNDX
$20.08
-$0.33-1.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -243.25M | -285.42M | -311.58M | -334.99M | -331.20M |
| Total Depreciation and Amortization | 10.00K | 6.00K | 3.00K | 2.00K | 5.00K |
| Total Amortization of Deferred Charges | 172.00K | 228.00K | 259.00K | 197.00K | 142.00K |
| Total Other Non-Cash Items | 45.85M | 41.53M | 40.81M | 36.49M | 32.23M |
| Change in Net Operating Assets | -80.94M | -79.32M | -40.37M | -4.36M | 12.31M |
| Cash from Operations | -278.16M | -322.98M | -310.88M | -302.67M | -286.52M |
| Capital Expenditure | -187.00K | -187.00K | -131.00K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 234.47M | 290.22M | -60.38M | -46.10M | -26.23M |
| Cash from Investing | 234.28M | 290.04M | -60.52M | -46.10M | -26.23M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 20.66M | 13.68M | 11.53M | 8.35M | 8.48M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 343.65M | 343.65M | 343.65M |
| Cash from Financing | 20.66M | 13.68M | 355.18M | 352.00M | 352.13M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -23.22M | -19.27M | -16.21M | 3.24M | 39.38M |